| P2093 | author name string | Dane R Liston | |
| | Myrtle Davis | |
| P2860 | cites work | A novel model for prediction of human drug clearance by allometric scaling | Q46549072 |
| | Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model | Q54631341 |
| | Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts | Q69459647 |
| | The route of absorption of intraperitoneally administered compounds | Q71828308 |
| | Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1 | Q78206927 |
| | Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches | Q83506421 |
| | Dose translation from animal to human studies revisited | Q29618049 |
| | Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? | Q33296440 |
| | Predicting clearance in humans from in vitro data | Q33820126 |
| | The resurgence of covalent drugs | Q34174891 |
| | CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment | Q34381754 |
| | Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 |
| | Intraperitoneal therapy for peritoneal cancer | Q34789701 |
| | Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development | Q35761430 |
| | Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance. | Q35975826 |
| | The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. | Q36886681 |
| | Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). | Q39570599 |
| | Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. | Q42258728 |
| | A proposal regarding reporting of in vitro testing results | Q42552338 |
| | A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity | Q44004732 |
| | Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics | Q46095574 |
| | Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species | Q46146990 |
| | Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies | Q46541545 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3489-3498 | |
| P577 | publication date | 2017-03-31 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies | |
| P478 | volume | 23 | |